S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

ALX Oncology Stock Price, News & Analysis (NASDAQ:ALXO)

$12.26
+3.01 (+32.54%)
(As of 12/8/2023 ET)
Compare
Today's Range
$10.15
$13.50
50-Day Range
$4.81
$12.26
52-Week Range
$3.94
$13.50
Volume
3.85 million shs
Average Volume
535,468 shs
Market Capitalization
$610.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.07

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
63.7% Upside
$20.07 Price Target
Short Interest
Bearish
17.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of ALX Oncology in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.61) to ($3.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

310th out of 945 stocks

Pharmaceutical Preparations Industry

106th out of 423 stocks


ALXO stock logo

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

ALXO Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
ALX Oncology (NASDAQ: ALXO)
Piper Sandler Keeps Their Buy Rating on ALX Oncology Holdings (ALXO)
What's Going On With ALX Oncology Stock?
ALX Oncology Announces Pricing of Public Offering
ALX Oncology Announces Proposed Public Offering
The Latest Analyst Ratings for ALX Oncology Holdings
Why ALX Oncology Stock Is Skyrocketing Today
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
71
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.07
High Stock Price Target
$34.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+66.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-123,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.18 million
Book Value
$6.46 per share

Miscellaneous

Free Float
24,760,000
Market Cap
$610.78 million
Optionable
Not Optionable
Beta
1.39
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 71)
    Executive Chairman
    Comp: $84k
  • Mr. Jason W. LettmannMr. Jason W. Lettmann (Age 46)
    CEO & Director
    Comp: $60.5k
  • Dr. Jaume Pons Ph.D. (Age 57)
    Founder, President, Director & Chief Scientific Officer
    Comp: $856.29k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 61)
    Chief Financial Officer
    Comp: $631.11k
  • Dr. Sophia Randolph M.D. (Age 55)
    Ph.D., Chief Medical Officer & Director
    Comp: $637.24k
  • Dr. Michael Chang Ph.D.
    Vice President of Operations
  • Ms. Shelly Pinto (Age 47)
    Senior VP of Finance & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Christopher Byrd J.D.
    Ph.D., General Counsel
  • Dr. Athanasios Tsiatis M.D.
    Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D.
    M.S., Senior Vice President of Drug Safety & Pharmacovigilance














ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price target for 2024?

8 Wall Street research analysts have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they predict the company's stock price to reach $20.07 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2023?

ALX Oncology's stock was trading at $11.27 on January 1st, 2023. Since then, ALXO stock has increased by 8.8% and is now trading at $12.26.
View the best growth stocks for 2023 here
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.38.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

(ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (13.59%), Federated Hermes Inc. (0.61%), Charles Schwab Investment Management Inc. (0.34%), Hsbc Holdings PLC (0.09%), Barclays PLC (0.07%) and J.P. Morgan Private Wealth Advisors LLC (0.05%). Insiders that own company stock include G Walmsley Graham, Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -